{"schema_version":"secwatch.filing_event.v1","accession":"0001731122-25-000067","form_type":"8-K","ticker":"LNAI","cik":"0001527728","company_name":"Lunai Bioworks Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.898424+00:00","generated_at":"2026-05-28T03:11:21.239716+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Renovaro appoints Nathen Fuentes as CFO; removes interim CFO Simon Tarsh","bullets":["Nathen Fuentes, age 42, appointed CFO effective January 6, 2025; previously CFO at Telomir Pharmaceuticals (Sep 2023 – Jun 2024).","Base salary of $280,000 per year; performance bonus up to $40,000 annually, pro-rated for 2025.","Equity incentive grant of 250,000 stock options vesting quarterly over eight quarters; discretionary equity grant on first anniversary.","If terminated without cause or for good reason: six months base salary, COBRA reimbursement for 6 months, accelerated vesting of time-based awards.","Simon Tarsh removed as Interim CFO in connection with Fuentes' appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-25-000067","json":"https://secwatch.observer/filing/0001731122-25-000067.json","markdown":"https://secwatch.observer/filing/0001731122-25-000067.md","text":"https://secwatch.observer/filing/0001731122-25-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/0001731122-25-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/e6282_8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:11:21.239716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7818596748","claim":"Simon Tarsh was removed as Interim Chief Financial Officer at Lunai Bioworks Inc..","evidence_excerpt":"In connection with Mr. Fuentes’ appointment as Chief Financial Officer, Simon Tarsh was removed as Interim Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/0001731122-25-000067-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"removed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"a1b35e7f52","claim":"Nathen Fuentes was appointed as Chief Financial Officer at Lunai Bioworks Inc..","evidence_excerpt":"Effective January 6, 2025, the board of directors (the “ Board ”) of Renovaro Inc. (the “ Company ” or “ Renovaro ”) appointed Nathen Fuentes, age 42, as Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1527728/000173112225000067/0001731122-25-000067-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}